Bristol-Myers Squibb Co vs Macy's Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $132.45B), while Macy's Inc trades at $24.53 (market cap $6.68B). The key difference: Bristol-Myers Squibb Co is far larger — about 19.8× Macy's Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BMY | M | |
|---|---|---|
Market Cap | $132.45B | $6.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $26.21 |
52-Week Low | $42.60 | $12.73 |
Enterprise Value | $166.44B | $10.50B |
Dividend Yield | 3.89% | 3.02% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →